Epidermolysis Bullosa

That this House welcomes the recent identification of anti-inflammatory drugs, which are already available within the NHS, that could be successful in treating Epidermolysis Bullosa (EB); notes that around 5,000 people in the UK are currently living with EB, a group of rare genetic disorders that result in fragile and blistered skin; recognises the work of DEBRA in spending £1.8 million on charitable activities in 2021, including nearly £500,000 on research projects; and further welcomes DEBRA’s drug repurposing programme, which requires the Government to commit £10 million of financial support to accelerate clinical trials and secure approved treatments for EB sufferers in the UK.